BBOT

NASDAQ 已收盘

BridgeBio Oncology Therapeutics

1.86 USD
▲+0.06+3.05%
盘后 1.89 +1.61%
2026-11-19
市值
$145.25M
市盈率
—
EPS
-2.14
股息率
—
52 周区间
1.79 – 14.87
成交量
366.74K
Beta
0.85
目标价
20.91
52W 低 1.7952W 高 14.87
价格走势

公司简介

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical...